Psi Cro Pharma India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-07-2024
- Paid Up Capital ₹ 1.00 M
as on 06-07-2024
- Company Age 16 Year, 3 Months
- Last Filing with ROC 31 Dec 2022
- Revenue 20.36%
(FY 2020)
- Profit 1.78%
(FY 2020)
- Ebitda 15.35%
(FY 2020)
- Net Worth 15.74%
(FY 2020)
- Total Assets 19.20%
(FY 2020)
About Psi Cro Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Srikanth Narasimhan, Nikolay Sinakevich, Andrey Kozhemyakin, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999KA2008FTC047698
- Company No.
047698
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
05 Sep 2008
- Date of AGM
31 May 2023
- Date of Balance Sheet
31 Dec 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Psi Cro Pharma India?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srikanth Narasimhan  | Director | 30-May-2014 | Current |
Nikolay Sinakevich  | Director | 23-Dec-2008 | Current |
Andrey Kozhemyakin  | Director | 19-Apr-2021 | Current |
| Albertine Varone | Director | 19-Apr-2021 | Current |
Financial Performance and Corporate Structure Insights of Psi Cro Pharma India.
Psi Cro Pharma India Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 20.36% increase. The company also saw a slight improvement in profitability, with a 1.78% increase in profit. The company's net worth Soared by an impressive increase of 15.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Psi Cro Pharma India?
In 2020, Psi Cro Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Teknion Furniture Systems (India) Private LimitedActive 19 years 7 monthsSrikanth Narasimhan is a mutual person
Napa Software Services India Private LimitedActive 17 years 23 daysSrikanth Narasimhan is a mutual person
Tk Manufacturing (India) Private LimitedActive 1 year 4 monthsSrikanth Narasimhan is a mutual person
- Gis Integrated Supply India Private LimitedActive 5 years 5 months
Srikanth Narasimhan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Psi Cro Pharma India?
Unlock and access historical data on people associated with Psi Cro Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Psi Cro Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Psi Cro Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
